▲ Peaking
Business
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its cancer-drug pipeline through the acquisition of UK-based biotech firm Myricx Bio in a deal valued up to $1.5 billion.
Adc
1 trends tracked about this subject — the full history, oldest to newest below.